| 1 |
32572160 | Functional genomics identifies new synergistic therapies for retinoblastoma. | 2020 Jul |
1 |
| 2 |
32765594 | Elucidation of Mechanisms of Topotecan-Induced Cell Death in Human Breast MCF-7 Cancer Cells by Gene Expression Analysis. | 2020 |
2 |
| 3 |
30472223 | Pifithrin-α enhancing anticancer effect of topotecan on p53-expressing cancer cells. | 2019 Feb 1 |
1 |
| 4 |
31088908 | HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity. | 2019 Aug |
3 |
| 5 |
26848703 | Thymoquinone from Nigella sativa Seeds Promotes the Antitumor Activity of Noncytotoxic Doses of Topotecan in Human Colorectal Cancer Cells in Vitro. | 2016 Mar |
1 |
| 6 |
25667043 | Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells. | 2015 Apr 1 |
4 |
| 7 |
25182801 | Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation. | 2014 Nov |
4 |
| 8 |
23376119 | p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells. | 2013 Apr 1 |
1 |
| 9 |
23406775 | Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent. | 2013 Apr 1 |
1 |
| 10 |
21765463 | Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. | 2012 Mar 1 |
2 |
| 11 |
22138446 | Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins. | 2012 Feb 1 |
3 |
| 12 |
22904680 | The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform. | 2012 Jul |
1 |
| 13 |
23024792 | The inhibition of autophagy sensitises colon cancer cells with wild-type p53 but not mutant p53 to topotecan treatment. | 2012 |
9 |
| 14 |
20875401 | Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells. | 2011 Jan 15 |
1 |
| 15 |
22101337 | Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. | 2011 Dec 1 |
4 |
| 16 |
19812371 | Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage. | 2010 Jan |
6 |
| 17 |
20038611 | The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. | 2010 Mar |
1 |
| 18 |
20515774 | Regulation of p53 isoform expression in renal cell carcinoma. | 2010 Jun 1 |
1 |
| 19 |
20662736 | Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2. | 2010 Aug |
2 |
| 20 |
18802408 | Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation. | 2008 Oct |
6 |
| 21 |
17496931 | UVC inhibits HIF-1alpha protein translation by a DNA damage- and topoisomerase I-independent pathway. | 2007 Oct 18 |
1 |
| 22 |
17610067 | Differential gene expression in anticancer drug- and TRAIL-mediated apoptosis in renal cell carcinomas. | 2007 Sep |
1 |
| 23 |
17636258 | Activation of targeted necrosis by a p53 peptide: a novel death pathway that circumvents apoptotic resistance. | 2007 Sep 14 |
1 |
| 24 |
17718196 | Antiproliferation in human EA.hy926 endothelial cells and inhibition of VEGF expression in PC-3 cells by topotecan. | 2007 Jul |
1 |
| 25 |
15890420 | Cell cycle effects of topotecan alone and in combination with irradiation. | 2005 May |
6 |
| 26 |
16127286 | p53 Gene status and response to topotecan-containing chemotherapy in advanced ovarian carcinoma. | 2005 |
3 |
| 27 |
16204064 | Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. | 2005 Oct 1 |
6 |
| 28 |
14639618 | An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression. | 2004 Jan 10 |
1 |
| 29 |
15724841 | Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01. | 2004 Oct |
5 |
| 30 |
12684687 | The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. | 2003 May |
1 |
| 31 |
12698201 | Tracking the cell cycle origins for escape from topotecan action by breast cancer cells. | 2003 Apr 22 |
1 |
| 32 |
12782583 | Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. | 2003 Jun 1 |
2 |
| 33 |
11166732 | Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. | 2001 Jan 19 |
1 |
| 34 |
10857993 | Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines. | 2000 May |
4 |
| 35 |
10505042 | Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. | 1999 May |
2 |
| 36 |
9732400 | Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression. | 1998 Sep |
3 |
| 37 |
9743293 | Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. | 1998 Sep |
1 |
| 38 |
9816112 | Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. | 1996 Oct |
1 |